ipopba Elevator Pitch I have a Hold investment rating for Accolade, Inc. (NASDAQ:ACCD) stock. My prior April 5, 2024 write-up drew attention to Accolade's latest corporate developments like the addition of new partners. The current update reviews ACCD's Q1 FY 2025 (YE February 28, 2025) financial performance and evaluates the company's financial prospects. Accolade's Q1 results benefited from a favorable timing difference, but its updated full-year guidance was mixed. ACCD lowered its FY 2025 top line guida ...

财务数据和关键指标变化 - 第一季度收入约为1.105亿美元,同比增长18% [15] - 调整后EBITDA亏损330万美元 [16] - 调整后毛利率提升至47.8%,去年同期为43.5% [16] - 现金、现金等价物和有价证券总额为2.31亿美元 [17] 各条业务线数据和关键指标变化 - 直接面向消费者的PlushCare业务预计今年增长约20%,增速略低于之前预期 [20][21] - 基于平台的Expert Medical Opinion和企业级虚拟初级护理业务将继续快于整体业务增长 [22] 各个市场数据和关键指标变化 - 总体需求环境保持强劲,公司在本年度早期阶段已签署了一笔数百万美元的服务合同 [23] - 公司将保持定价和利润率方面的纪律,不会为了追求业务而牺牲利润 [23] 公司战略和发展方向及行业竞争 - 公司选择智能、有利可图的增长和确定的底线,这种方法可为客户、员工、合作伙伴和股东带来最大价值 [27][28][29] - 公司将继续投资人工智能、紧密集成的产品以及市场领先的临床质量和能力 [30] - 公司目前拥有1200多家客户和1400万会员,2000多名员工致力于为客户和会员提供更好的医疗体验 [30] - 公司在过去15年中建立了业务,未来也将继续发挥这一优势 [30] 管理层对经营环境和未来前景的评论 - 公司选择智能、有利可图的增长和确定的底线,以应对当前的市场因素和对可靠的底线收益预测的需求 [8][9][19] - 公司将收紧一些营销支出,专注于最有利可图的机会,以确保实现利润目标 [20][21][22][24] - 公司将保持定价和利润率方面的纪律,不会为了追求业务而牺牲利润 [23] - 公司认为,在新兴市场中,专注于客户、采取可扩展的盈利策略的公司最终将成为赢家 [12] 其他重要信息 - 公司将在今年晚些时候举行分析师日,届时将提供更多关于长期计划的细节 [10] - 公司认为,个性化医疗保健建立在有效平台之上的类别已在市场上得到很好的确立,需求持续强劲 [11] 问答环节重要的提问和回答 问题1 **Richard Close 提问** 提问了关于收入指引下调的3个主要原因 [32] **Rajeev Singh 和 Steve Barnes 回答** 1) 公司选择适度收紧收入指引,以确保实现利润目标 [33][34][35][36][37][38][39][40][41] 2) 公司将收紧一些营销支出,专注于最有利可图的机会 [38][39][40][41][42] 3) 公司将保持定价和利润率方面的纪律,不会为了追求业务而牺牲利润 [41][42][43] 问题2 **Craig Hettenbach 提问** 提问了关于基于使用的收入以及核心业务咨询服务的增长预期 [44] **Steve Barnes 回答** 1) 公司对基于使用的收入有较好的可见性,预计将继续快于整体业务增长 [45][46][47] 2) 咨询服务业务的年度经常性收入(ARR)过去2年增长20%-30%,今年增长前景乐观 [47] 问题3 **Michael Cherny 提问** 提问了关于本季度收入超预期以及全年收入指引下调的具体原因 [49] **Steve Barnes 回答** 1) 收入指引下调主要是由于基于使用的收入和直接面向消费者的PlushCare业务收入下调 [51][52][53] 2) 这些收入下调主要是为了控制相关营销支出,以确保利润目标 [51][52][53]

Accolade (ACCD) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.52 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 27.08%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.10, delivering a surprise of 9.09%.Over the last four quarters, the company has surpassed consen ...

业绩总结 - Accolade Inc. 在2024财年预计实现4.6亿至4.75亿美元的营收[28] - Accolade Inc. 在2025财年预计实现1,500万至2,000万美元的调整后息税折旧及摊销前利润（EBITDA）[28] - Accolade Inc. 在过去几年中保持了30%的年复合增长率[30] - Accolade Inc. 在过去几年中实现了稳健的财务增长，朝着盈利目标取得进展[30] 用户数据 - Accolade Inc. 在过去几年中不断扩大可寻址市场，目前已拥有超过1400家客户[29] - FY24年有超过1200家客户[31] - FY24年没有任何一个客户占据5%以上的份额[31] 未来展望 - 财报中提到了长期目标，调整后的毛利率目标为50-55%[32] - 调整后的销售和市场费用占营收的比例目标为15-20%[33] - 调整后的总务和行政费用占营收的比例目标为7-9%[34] - 调整后的EBITDA利润率目标为15-20%[35] 新产品和新技术研发 - Accolade Inc. 在过去几年中推出了智能提供者匹配、COVID应对护理、整合护理等创新项目[28] 市场扩张和并购 - Accolade Inc. 在2020年7月进行了首次公开募股（IPO），随后在2020年10月和2021年3月进行了跟进发行和可转债发行[28] 负面信息 - 调整后的毛利、毛利率和EBITDA有一定的局限性，因为它们排除了某些非现金费用的影响[40]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ FORM 10-Q ______________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39348 ACCOLA ...

Exhibit 99.1 Accolade Announces Results for Fiscal First Quarter 2025 SEATTLE, June 27, 2024 -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2024. “Accolade's physician-led advocacy approach to solving the Physician Gap is increasing accessibility to healthcare and improving outcomes for the millions of lives we service. We will continue to push our leadership in Healthcare AI and a proven engagement model that is driving sustainable and profitab ...

SEATTLE, June 27, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2024. “Accolade's physician-led advocacy approach to solving the Physician Gap is increasing accessibility to healthcare and improving outcomes for the millions of lives we service. We will continue to push our leadership in Healthcare AI and a proven engagement model that is driving sustainable and profitable growth. Our focus remains on delivering a superior ...

SEATTLE, June 27, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2024. “Accolade's physician-led advocacy approach to solving the Physician Gap is increasing accessibility to healthcare and improving outcomes for the millions of lives we service. We will continue to push our leadership in Healthcare AI and a proven engagement model that is driving sustainable and profitable growth. Our focus remains on delivering a superior ...

SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal first quarter 2025 financial results on Thursday, June 27, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI651ad635 ...

SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal first quarter 2025 financial results on Thursday, June 27, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI651ad635 ...